About Avivagen
Avivagen is a publicly listed company based in Ottawa (Canada) founded in 2005. Biopharmaceutical products for livestock feed additives are developed. Its focus areas include HealthTech, Veterinary HealthTech and Health Supplements.
Company details
Avivagen was founded in 2005 in Ottawa, Canada, and operates in the biopharmaceutical sector focused on animal health. A patented technology known as OxC-Beta, involving fully oxidized beta-carotene, has been developed to address inflammation and immune function in livestock. This approach aims to reduce antibiotic use for health and growth. Commercial products include OxC-beta for livestock, Vivamune vital health chews, and Oximunol chewable tablets.
- Headquarters Ottawa, Canada
- Stage Public
- SectorsHealthcare
- Website avivagen.com
- Social LinkedIn X Facebook
- Legal Name Avivagen, Inc.
- Annual Revenue$689.17 K (USD)-34.11as on Oct 31, 2022
- Net Profit-$4.45 M (USD)13.75as on Oct 31, 2022
- EBITDA-$3.57 M (USD)-6.38as on Oct 31, 2022
- Investors
Funding Insights of Avivagen
- Total Rounds 12
- First Round $357,427
(Oct 2012)
- Investors Count 1
Latest 10 of 12 funding rounds of Avivagen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2022 | Post-IPO | – | – | – | |
| Oct 2022 | Post-IPO | – | – | – | |
| Jul 2022 | Post-IPO | – | – | – | |
| May 2022 | Post-IPO | – | – | – | |
| Apr 2022 | Post-IPO | – | – | – | |
| Jan 2020 | $1.75M | Post-IPO | – | – | – |
| Jan 2020 | $1.25M | Post-IPO | – | – | – |
| Mar 2019 | $5M | Post-IPO | – | – | – |
| Mar 2019 | Debt – Conventional | – | – | – | |
| Jun 2016 | $3.6M | Post-IPO | – | – | – |
1 investors in total: 1 institutional.
Investors in Avivagen
Avivagen has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Pathfinder Asset Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Asset management services are provided for motivated investors. | paml.ca | Vancouver, Canada |
Investor details for Avivagen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Avivagen
1 people are tracked at Avivagen (1 in leadership).
| Name | Role | Group |
|---|---|---|
Kym Anthony | Chief Executive Officer | Leadership |
Complete people profiles for Avivagen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Avivagen
Avivagen is a publicly listed company on the OTC with ticker symbol VIVXF in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date01 Oct 2007
- Listed onTSX-V: VIV
- Listed entityAvivagen, Inc.
- Exchange sectorHealth technology
- ISINCA05382F2026
- Share price$0.00 (-99% on the day) · 2026-05-11
- Volume (last session)100
- Analyst consensusNo rating
Financials of Avivagen
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2022 | $689,170 | -$4.5M | -$3.6M |
| 2021 | $1.1M | -$5.2M | -$3.4M |
Detailed financial statements for Avivagen
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Avivagen
4 dated milestones of Avivagen across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Avivagen is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $357K.
- Funding Latest funding round, Post-IPO,.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Avivagen
Complete news archive for Avivagen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Avivagen
Avivagen was founded in 2005 and raised its 1st funding round 7 years after it was founded.
Avivagen is headquartered in Ottawa, Canada. It is registered at Ottawa, Ontario, Canada.
Annual revenue of Avivagen is $689.17K as on Oct 31, 2022.
Avivagen was founded in 2005 in Ottawa, Canada, and operates in the biopharmaceutical sector focused on animal health. A patented technology known as OxC-Beta, involving fully oxidized beta-carotene, has been developed to address inflammation and immune function in livestock. This approach aims to reduce antibiotic use for health and growth. Commercial products include OxC-beta for livestock, Vivamune vital health chews, and Oximunol chewable tablets.
Yes, Avivagen is publicly traded on OTC under the ticker symbol VIVXF.
Avivagen has 1 investor. Key investors include Pathfinder Asset Management.